EIKN
Eikon Therapeutics, Inc.
Eikon Therapeutics, Inc. (EIKN) has 2 SEC Form 4 filings (11 transaction rows) in the rolling window, disclosed by 1 distinct insider. Most recent filing: Feb 10, 2026.
Insiders have net bought $38.1M over the trailing 6 months. The largest single insider purchase in this window was $38.1M by 10% Owner Column Group IV GP, LP on Feb 6, 2026.
- Industry:Biotechnology
- CEO:Roger Perlmutter
- Employees:384
- HQ:Millbrae, CA, US
- IPO:2026-02-05
Insider Buying
$38.1M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
1
in the rolling window
| Source | ||||||
|---|---|---|---|---|---|---|
Column Group IV GP, LPFirst filing | 10% Owner | Purchase | 2,117,760 | $38.1M | Feb 9 | SEC ↗ |
Related companies
Eikon Therapeutics, Inc. is in the Healthcare sector.